N4 Pharma Raises £1.75 Million to Advance Nuvec® Platform

The latest update is out from N4 Pharma ( (GB:N4P) ).

N4 Pharma has announced a successful fundraise of £1,750,000 through a placing and subscription of new ordinary shares. The proceeds will be used to advance the Nuvec® platform towards commercialization, focusing on RNA therapeutics, which is expected to significantly enhance the company’s value. The funds will support the completion of key data packages required for platform partnerships and licensing deals, with a focus on demonstrating Nuvec®’s unique capabilities in RNA delivery. The company has also engaged experienced consultants to oversee the execution of this work, aiming to secure platform partnering deals swiftly.

More about N4 Pharma

N4 Pharma is a pre-clinical biotech company focused on developing Nuvec®, a proprietary gene delivery system designed to enable advanced therapies for cancer and other diseases. The company is working towards securing significant licensing deals for its Nuvec® platform by building a comprehensive preclinical data set and advancing towards first-in-human clinical data.

YTD Price Performance: -18.27%

Average Trading Volume: 2,330,698

Technical Sentiment Signal: Buy

Current Market Cap: £5.16M

See more data about N4P stock on TipRanks’ Stock Analysis page.